Mid Atlantic Bio Angels

Yaniv Sneor founded the group and has been its public-facing leader, representing the investment process and criteria in external media such as "The Business of Biotech" podcast. The group operated through a membership structure where individual and corporate members would participate in funding decisions. Specific internal investment committee details beyond Sneor's leadership are not publicly documented.

No. The firm's own portfolio page explicitly states that the group is "no longer active." No date for cessation of new investments is provided, but the language applies to the portfolio page in the present tense as of the latest site capture.

The group operated primarily through direct angel investments by its members. It also maintained a co-investment structure called a Sidecar Fund, which pooled capital from members to participate alongside individual investments. The group did not publicly describe itself as committing to outside venture funds.

The group targeted early-stage life science companies, offering a separate process for companies deemed too early for investment — allowing them to pitch for feedback without seeking immediate funding. This suggests a focus on seed and early-stage biotech ventures, though no formal stage classification was published.

The group invested exclusively in life science companies. Its mandate was sector-specific to biotechnology and healthcare-related life sciences, with no stated restrictions within that broad category. The group did not invest outside the life sciences vertical.